Nextseed's next phase

Houston investment platform acquired, new partnership grows investor access

With the acquisition, Youngro Lee, co-founder and CEO of NextSeed, has been named the COO of Republic. Courtesy of NextSeed

A growing New York-based private investment platform has acquired Houston-based NextSeed, according to announcements from both companies.

Republic announced the acquisition Monday, November 16, and appointed Youngro Lee, co-founder and CEO of NextSeed, as Republic's new COO. It's the third acquisition for Republic this year. Fig, a gaming-focused platform, and Compound, a real estate-focused platform, both joined the Republic family, allowing investors access to other industries.

"The NextSeed acquisition is just the latest milestone for Republic as we deliver the most expansive platform of marketplace offerings and investment types for private investors globally," Republic CEO Kendrick Nguyen says in a release.

Lee founded NextSeed with CMO Abe Chu and CTO Bob Dunton six years ago following the passage of the JOBS Act in 2012, that allowed smaller investments from non-accredited investors. Since then, NextSeed has facilitated $20 million in investments from 25,000 members into 75 local businesses.

It's a pivotal moment for the private investment community as just two weeks ago the SEC announced changes to Regulation Crowdfunding that included raising the fundraising caps from $1.07 million to $5 million. Between the new regulations and the new Republic deal, investing on NextSeed's platform will grow in scale.

"Now, by partnering with Republic, we believe that we can achieve so much more together for our entire business and investor community," NextSeed's executive team says in an email to investors. "We have known and worked with the Republic team for over four years, as both firms tried to strengthen and grow this industry since the very beginning of this movement."

Republic's founders are alums from AngelList and have made Republic one of the top private investing platforms in the industry with around 1 million members and more than $200 million facilitated through individual and institutional investors, according to the email.

According to NextSeed's email to its investors, little will change on the platform for investors, aside from access to new deals from Republic and its subsidiaries. Additionally, NextSeed will maintain its headquarters in Houston and the deal marks Republic's entrance into Houston and Texas.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News